Mercaptoethylguanidine (MEG) dihydrobromide is primarily used in research and pharmaceutical applications due to its antioxidant and cytoprotective properties. It is studied for its ability to scavenge reactive oxygen species (ROS) and protect cells from oxidative stress, making it a potential candidate for treating conditions linked to oxidative damage, such as ischemia-reperfusion injury, neurodegenerative diseases, and inflammation. Additionally, MEG has been explored for its role in mitigating the toxic effects of certain chemotherapeutic agents, helping to preserve healthy tissues during cancer treatment. Its ability to interact with nitric oxide pathways also makes it relevant in studies related to cardiovascular health and endothelial function.